Sarepta Therapeutics SRPT has been analyzed by 28 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 17 | 7 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 5 | 2 | 0 | 0 |
| 2M Ago | 3 | 9 | 4 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $185.0, a high estimate of $235.00, and a low estimate of $128.00. This current average has increased by 6.54% from the previous average price target of $173.65.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive Sarepta Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Maintains | Outperform | $181.00 | $181.00 |
| Brian Abrahams | RBC Capital | Lowers | Outperform | $181.00 | $182.00 |
| David Hoang | Citigroup | Lowers | Neutral | $160.00 | $176.00 |
| Kristen Kluska | Cantor Fitzgerald | Lowers | Neutral | $152.00 | $167.00 |
| Biren Amin | Piper Sandler | Lowers | Overweight | $200.00 | $205.00 |
| Gavin Clark-Gartner | Evercore ISI Group | Lowers | Outperform | $179.00 | $185.00 |
| Gena Wang | Barclays | Lowers | Overweight | $203.00 | $226.00 |
| Brian Abrahams | RBC Capital | Announces | Outperform | $182.00 | - |
| Biren Amin | Piper Sandler | Maintains | Overweight | $205.00 | $205.00 |
| Gil Blum | Needham | Maintains | Buy | $235.00 | $235.00 |
| David Hoang | Citigroup | Raises | Neutral | $176.00 | $172.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $200.00 | $165.00 |
| Gavin Clark-Gartner | Evercore ISI Group | Raises | In-Line | $185.00 | $139.00 |
| Kostas Biliouris | BMO Capital | Raises | Outperform | $200.00 | $170.00 |
| Mani Foroohar | Leerink Partners | Raises | Outperform | $230.00 | $165.00 |
| Matthew Harrison | Morgan Stanley | Maintains | Overweight | $165.00 | $165.00 |
| Biren Amin | Piper Sandler | Maintains | Overweight | $157.00 | $157.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Neutral | $128.00 | $128.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $182.00 | $142.00 |
| Gena Wang | Barclays | Raises | Overweight | $226.00 | $185.00 |
| Brian Skorney | Baird | Raises | Outperform | $200.00 | $170.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $213.00 | $166.00 |
| Gil Blum | Needham | Raises | Buy | $235.00 | $166.00 |
| Kostas Biliouris | BMO Capital | Maintains | Outperform | $170.00 | $170.00 |
| Kostas Biliouris | BMO Capital | Maintains | Outperform | $170.00 | $170.00 |
| Biren Amin | Piper Sandler | Announces | Overweight | $157.00 | - |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $142.00 | $157.00 |
| Gil Blum | Needham | Maintains | Buy | $166.00 | $166.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sarepta Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Sarepta Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sarepta Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Sarepta Therapeutics analyst ratings.
Discovering Sarepta Therapeutics: A Closer Look
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Understanding the Numbers: Sarepta Therapeutics's Finances
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sarepta Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 38.93%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Sarepta Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.78% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sarepta Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.63%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Sarepta Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.19%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.27.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
